Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Lawrence Salamone Velilla

Nephrology San Juan, PR Medical Doctor

NPI 1346303880 CMS profile 771939

Ave Ponce De Leon #715 Pda 37 1/2, Clinicas Externas Hosp Auxilio Mutuo, San Juan, PR 00917

Open in the dashboard

General payments

$2,082

9 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lawrence Salamone Velilla of San Juan, PR is reported in the CMS Open Payments database as having received $2,082 across 9 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $50 1
2023 General $300 4
2022 General $1,732 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lawrence Salamone Velilla
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Lawrence Salamone Velilla were reported at $50. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Lawrence Salamone Velilla Nephrology median Middle half National median
2019 $0 $236 $90–$588 $163
2020 $0 $135 $46–$364 $114
2021 $0 $202 $67–$551 $132
2022 $1,732 $242 $77–$695 $149
2023 $300 $254 $84–$766 $160
2024 $0 $300 $99–$852 $164
2025 $50 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Merck Sharp & Dohme Corporation $1,560 2 payments
  2. Alexion Pharmaceuticals, Inc. $115 1 payment
  3. Genzyme Corporation $90 1 payment
  4. Bard Peripheral Vascular, Inc. $82 1 payment
  5. Bayer HealthCare Pharmaceuticals Inc. $65 1 payment
  6. Calliditas Therapeutics US Inc. $60 1 payment
  7. Mallinckrodt Hospital Products Inc. $60 1 payment
  8. AstraZeneca Pharmaceuticals LP $50 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,500 1 payment
  2. Food and Beverage $582 8 payments
Products named General payments · program years 2022–2025
  1. KEYTRUDA $1,500 1 payment
  2. Kerendia $65 1 payment
  3. ACTHAR $60 1 payment
  4. TARPEYO $60 1 payment
  5. LOKELMA $50 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

3,088

Median for Internal Medicine: 777

Drug cost

$188,661

Median for Internal Medicine: $73,373

Branded share of claims

17.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 40 $45,892
Januvia Sitagliptin Phosphate Brand 19 $29,137
Janumet Sitagliptin Phos/Metformin Hcl Brand 19 $24,140
Synthroid Levothyroxine Sodium Brand 181 $21,520
Xarelto Rivaroxaban Brand 28 $20,141
Irbesartan Generic 102 $4,094
Losartan Potassium Generic 229 $3,135
Rosuvastatin Calcium Generic 134 $2,879
Simvastatin Generic 241 $2,500
Irbesartan-Hydrochlorothiazide Irbesartan/Hydrochlorothiazide Brand 44 $2,405

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$11,109

Medicare's payments for the services billed

Medicare patients

46

Average age 82

Services billed

124

24 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 41%
Arthritis 41%
Ischemic heart disease 37%
Osteoporosis 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

9 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record